title: Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells.
abstract: BACKGROUND
  The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP)-resistant oral squamous cell carcinoma (OSCC) cell line and its parental cell line.
  
  
  METHODS
  CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment.
  
  
  RESULTS
  KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells.
  
  
  CONCLUSIONS
  These data suggested that satraplatin has antitumor activity against the CDDP-resistant OSCC cells. The mechanism of cross-resistance to platinum agents seems to be multifactorial.
authors.affiliation: Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Yamano
authors.forename: Masashi
authors.initials: M
authors.lastname: Shiiba
authors.forename: Kenji
authors.initials: K
authors.lastname: Negoro
authors.forename: Ken
authors.initials: K
authors.lastname: Nakatani
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kasamatsu
authors.forename: Masanobu
authors.initials: M
authors.lastname: Yamatoji
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sakuma
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogoshi
authors.forename: Manabu
authors.initials: M
authors.lastname: Iyoda
authors.forename: Keiji
authors.initials: K
authors.lastname: Shinozuka
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Yokoe
authors.forename: Takeshi
authors.initials: T
authors.lastname: Wada
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Fujita
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Iwasawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Takiguchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Tanzawa
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Uzawa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology*; D016001:Confidence Intervals; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D006801:Humans; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; C081294:satraplatin; D002945:Cisplatin